Trial Profile
A Retrospective, Multicenter Study to Investigate the Outcomes of Vedolizumab for the Treatment of Steroid-Resistant Severe Intestinal Acute Graft-Versus-Host Disease (aGvHD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2018 New trial record
- 24 Oct 2018 Results published in the Bone Marrow Transplantation Journal.